Back to search

Article

Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms and myelodysplastic neoplasms/acute myeloid leukemia undergoing allogeneic transplantation

2026-06-05

Abstract excerpt

<title>Abstract</title> <p> Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for myelodysplastic neoplasms/syndromes (MDS), but post-transplant relapse continues to limit long-term survival. Reliable identification of patients at high relapse risk remains lacking. A cohort of 192 patients with MDS or MDS/acute myeloid leukemia undergoing allo-HSCT was analyzed to a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dc5181c0-f77a-5ab9-8f11-1ef589c09ee4
DOI
10.21203/rs.3.rs-9867217/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms and myelodysplastic neoplasms/acute myeloid leukemia undergoing allogeneic transplantationDOI 10.21203/rs.3.rs-9867217/v1
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell TransplantationSemantic proximity
Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.Semantic proximity
Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.Semantic proximity
Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Semantic proximity
Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.Semantic proximity
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity
Relapse assessment following allogeneic SCT in patients with MDS and AML.Semantic proximity
Monitoring of Post-Transplant MLL-PTD as Minimal Residual Disease Can Predict Relapse After Allogeneic HSCT in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeSemantic proximity
Pre-emptive Detection and Evolution of Relapse in Acute Myeloid Leukemia by Flow Cytometric Measurable Residual Disease SurveillanceSemantic proximity
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.Semantic proximity
The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell TransplantationSemantic proximity
Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantationSemantic proximity
Select a neighboring publication to make it the new centre.